A class of diabetes drugs known as GLP-1 agonists has recently taken the pharmaceutical and weight loss industries by storm. This is because GLP-1 agonists suppress appetite and slow gastric emptying, which makes you feel full faster and longer.
While results can be significant, this off-label weight management method carries risks for both the member and the plan sponsor.
The Risks
• Clinical Uncertainty
>> Currently, only two GLP-1 agonists have been FDA reviewed and approved for weight loss.
>> Without FDA review, there is no way to know if these drugs are safe and effective for their intended use. Unapproved drugs have resulted in patient harm.
• Cost Driver
>> Outside of specialty drugs, diabetic drugs are a leading cost-driver in prescription benefits plans.
>> The recent uptick in the use of GLP-1 agonists for weight loss can exponentially increase drug spend for the plan, especially if the plan does not knowingly cover weight loss drugs.
TrueScripts Protection
• Clinical Certainty
>> To ensure that GLP-1 agonists are being used for FDA-approved conditions and in accordance with plan coverage parameters, Prior Authorizations (PA) for these drugs have been put in place.
>> No pharmacy ownership and use of an independent PA provider ensures that each drug and patient receives an accurate, unbiased clinical review.
• Cost Containment
>> As part of our Brand Care Program, we work to qualify many GLP-1 agonists to be received at a discounted rate.
>> When applicable, our team will explore international sourcing options to obtain the best pricing for these drugs.
>> We understand that diabetic comorbidities can drive costs exponentially, so we will work with clients to develop a benefits plan design best suited for the needs of their unique population.
Drug List
GLP-1 agonists - work by triggering insulin release and blocking sugar production in the liver
• Ozempic (semaglutide) – once weekly injection
>> Can help lower the risk of heart attack and stroke, plus potential kidney benefits
>> Not approved for weight loss
• Rybelsus – oral semaglutide (Ozempic) taken daily
>> Not approved for heart-related benefits or weight loss
• Trulicity (dulaglutide) – once weekly injection
>> Has heart and kidney benefits
>> Not approved for weight loss and less weight loss noted compared to semaglutide
• Victoza (liraglutide) – once daily injection
>> Has heart benefits and potentially kidney benefits
>> Not approved for weight loss and less weight loss noted compared to semaglutide
• Wegovy – higher dose semaglutide (Ozempic)
>> Approved for weight loss
• Saxenda – higher dose liraglutide (Victoza)
>> Approved for weight loss; studies showed greater weight loss with Wegovy
GLP-1/GIP agonists - newer class of medication that works by mimicking 2 gut hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
• Mounjaro – approved to treat Type 2 diabetes and the FDA is fast-tracking it’s review for weight loss approval
>> Head-to-head with Ozempic showed better Hemoglobin A1C reduction and greater weight loss
Zepbound (tirzepatide)– FDA approved for chronic weight management that activates both GIP and GLP-1 hormone receptors•
Factors for Choosing Which GLP-1 Agonist Is Right for You:
• Age – only some drugs are approved for children
• Underlying Conditions – added heart and kidney protection in some drugs
• Treatment Preference – oral vs. injection, daily vs. weekly
• Treatment Goals
•
Body Mass Index (BMI)
• Insurance Coverage
Please reach out to the TrueScripts team with any questions or concerns you may have.
We are happy to provide you with answers and Amazing Care!
Proud Members Of
TrueScripts. All Rights Reserved.